Jana Fassunke

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes.

Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes.

Journal: The Journal of molecular diagnostics : JMD

Published: February 11, 2026

Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes.

Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes.

Journal: The Journal of molecular diagnostics : JMD

Published: February 11, 2026

CuMo-a program to strengthen molecular diagnostics in pathology

CuMo-a program to strengthen molecular diagnostics in pathology

Journal: Pathologie (Heidelberg, Germany)

Published: January 29, 2026

Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.

Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 12, 2026

MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition.

MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition.

Journal: JTO clinical and research reports

Published: July 30, 2025

Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.

Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 17, 2025

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

Journal: ESMO open

Published: August 15, 2023

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 25, 2023

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.

Journal: JCO precision oncology

Published: April 20, 2023

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.

Journal: Journal for immunotherapy of cancer

Published: September 18, 2022

Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD).

Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD).

Journal: International journal of molecular sciences

Published: July 27, 2022

Genomic ALK alterations in primary and relapsed neuroblastoma.

Genomic ALK alterations in primary and relapsed neuroblastoma.

Journal: British journal of cancer

Published: July 04, 2022

Showing 1-12 of 57

Last Updated: 09/26/2026